What is the recommended schedule for Hepatitis B (HBV) vaccination?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Hepatitis B Vaccination Schedule

The standard recommended schedule for Hepatitis B vaccination is a 3-dose series administered at 0,1, and 6 months for most individuals, with specific modifications for different age groups and special populations. 1

Standard Vaccination Schedules by Age Group

Infants

  • Infants born to HBsAg-negative mothers should receive:

    • First dose: at birth (within 24 hours)
    • Second dose: at 1-2 months of age
    • Third dose: at 6 months of age 1
  • Infants born to HBsAg-positive mothers should receive:

    • First dose: within 12 hours of birth (along with HBIG)
    • Second dose: at 1-2 months of age
    • Third dose: at 6 months of age 1

Children and Adolescents

  • Children who were not vaccinated as infants should follow:

    • 3-dose schedule: 0,1, and 6 months, OR
    • Alternative 2-dose schedule: adult formulation at 0 and 4-6 months (for specific age groups) 1
  • For children 5-10 years and adolescents 11-16 years, an alternative schedule of 0,12, and 24 months may be considered for those at low risk of immediate exposure 2, 3

Adults

  • Standard adult schedule (≥18 years):
    • 3 doses at 0,1, and 6 months (20 mcg per dose) 1, 2
    • Alternative schedule: 0,1,2, and 12 months for certain populations at higher risk 2

Special Populations

Chronic Kidney Disease and Hemodialysis Patients

  • For pre-dialysis CKD patients:

    • Recombivax HB: 10 μg at 0,1, and 6 months, OR
    • Engerix-B: 20 μg at 0,1, and 6 months 4
  • For dialysis-dependent patients:

    • Recombivax HB: 40 μg at 0,1, and 6 months, OR
    • Engerix-B: 40 μg at 0,1,2, and 6 months 4, 2
    • Annual anti-HBs testing with booster doses when levels fall below 10 mIU/mL 1, 4

Immunocompromised Adults

  • Higher doses (40 μg) at 0,1, and 6 months
  • Annual anti-HBs testing with booster doses when levels fall below 10 mIU/mL 1

Low Birth Weight Infants

  • For infants with birth weight <2000g:
    • Delay first dose until 1 month of age or hospital discharge (whichever comes first) if born to HBsAg-negative mothers 5
    • For infants born to HBsAg-positive mothers, administer first dose within 12 hours of birth regardless of weight, but this dose may not count toward the 3-dose series 6, 5

Post-Vaccination Testing

  • Post-vaccination serologic testing is recommended 1-2 months after completing the vaccination series for:

    • Infants born to HBsAg-positive mothers
    • Healthcare personnel
    • Hemodialysis patients
    • HIV-infected persons
    • Other immunocompromised individuals 1, 4
  • An anti-HBs level ≥10 mIU/mL indicates adequate protection 1, 4

Important Considerations and Pitfalls

  • Minimum intervals between doses must be maintained:

    • Between 1st and 2nd doses: 4 weeks
    • Between 2nd and 3rd doses: 8 weeks
    • Between 1st and 3rd doses: 16 weeks 1
  • Delaying the birth dose beyond 12 hours for infants born to HBsAg-positive mothers significantly increases infection risk 1, 7

  • Using standard adult doses (20 μg) instead of higher doses (40 μg) in dialysis patients results in inadequate immune response 4

  • Failure to check post-vaccination antibody titers in high-risk groups may leave patients unprotected 4

  • While longer intervals between doses (such as the 0,12,24-month schedule) produce adequate protection, the standard 0,1,6-month schedule generally produces higher final antibody levels 3, 8

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.